StemCell Therapy

Overview:

Nanomedicineis an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

Click Here to Get Sample Premium Report @https://www.trendsmarketresearch.com/report/sample/9807

Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

Market Analysis:

The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis:

Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players:

Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis:

At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Continue reading here:
Nanomedicine Market Shares, Strategies and Forecast Worldwide, 2017 to 2023 - The Haitian-Caribbean News Network

TEHRAN Iran ranked third for the highly cited researchers in the world among Islamic countries in 2020, according to the recently published report of Highly Cited Researchers by Web of Science.

Among the world's top researchers, 13 Islamic countries are listed, which hold a share of 3 percent (2.85%) among the world's top researchers.

Saudi Arabia with 120 researchers, Malaysia with 17, Iran with 12, and Turkey with 11 researchers have the highest number of highly cited researchers among Islamic countries.

To be included in the list of top researchers, all scientific activities over the last 10 years are evaluated at the international level, including the number of articles, number of citations, number of highly cited articles, number of citations to highly cited articles, as well as issues such as observing ethical principles in research.

So, approximately 6,389 researchers have been selected as highly cited researchers in 2020.

From Iran in 2020, similar to 2019, 12 top researchers have been included in the list of 6,389 top-cited researchers in the world.

The country's top researchers have been in the cross-field (6 people), agricultural sciences (2 people), mathematics (2 people), and engineering (2 people), respectively.

The United States is home to the highest number of Highly Cited Researchers, with 2,650 authors, representing 41.5 percent of the researchers on the list. China, home to 770 researchers is the second country has the highest concentration of Highly Cited Researchers in the world. The United Kingdom is also a hotbed of talent, with 514 authors, and Germany, Australia, Canada, the Netherlands, and France are all home to over 150 researchers each.

Top scientific articles

Iran's share of the world's top scientific articles is 3 percent, Gholam Hossein Rahimi Sheerbaf, the deputy science minister, said in October.

The countrys share in the whole publications worldwide is 2 percent, he noted, highlighting, for the first three consecutive years, Iran has been ranked first in terms of quantity and quality of articles among Islamic countries.

Iranian articles rank 16 and 15 in Web of Science and Scopus, respectively.

The Journal Citation Reports 2019 ranking includes 42 journals from Iran, including the Journal of Nanostructure in Chemistry with an impact factor of 4.077.

Iranian scientific journals such as the Journal of Nanostructures (affiliated to Kashan University), Nanomedicine Journal (Mashhad University of Medical Sciences), Journal of Nanoanalysis (Tehran University of Medical Sciences) were listed in the ESCI index of WOS database.

Moreover, the Journal of Water and Environmental Nanotechnology, Nanomedicine Research Journal, and International Nanoscience and Nanotechnology were also listed in the Scopus Index.

FB/MG

See the article here:
Iran ranks third for top researchers in Islamic world 2020 - Tehran Times

The global Nanorobots market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Nanorobots market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Nanorobots market. The authors of the report profile leading companies of the global Nanorobots market, such as Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, Nt-Mdt Spectrum Instruments, Witec They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Nanorobots market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Nanorobots market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Nanorobots market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Nanorobots industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Nanorobots market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2299604/global-nanorobots-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Nanorobots market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Nanorobots market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Nanorobots market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Nanorobots Market by Product: Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based

Global Nanorobots Market by Application: , Nanomedicine, Biomedical, Others

The report also focuses on the geographical analysis of the global Nanorobots market, where important regions and countries are studied in great detail.

Global Nanorobots Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2299604/global-nanorobots-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/eb52d0c501963b08754ff3f074b54556,0,1,global-nanorobots-market

Table Of Contents:

1 Market Overview of Nanorobots1.1 Nanorobots Market Overview1.1.1 Nanorobots Product Scope1.1.2 Market Status and Outlook1.2 Global Nanorobots Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Nanorobots Market Size by Region (2015-2026)1.4 Global Nanorobots Historic Market Size by Region (2015-2020)1.5 Global Nanorobots Market Size Forecast by Region (2021-2026)1.6 Key Regions, Nanorobots Market Size YoY Growth (2015-2026)1.6.1 North America Nanorobots Market Size YoY Growth (2015-2026)1.6.2 Europe Nanorobots Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Nanorobots Market Size YoY Growth (2015-2026)1.6.4 Latin America Nanorobots Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Nanorobots Market Size YoY Growth (2015-2026) 2 Nanorobots Market Overview by Type2.1 Global Nanorobots Market Size by Type: 2015 VS 2020 VS 20262.2 Global Nanorobots Historic Market Size by Type (2015-2020)2.3 Global Nanorobots Forecasted Market Size by Type (2021-2026)2.4 Nanomanipulator2.5 Bio-Nanorobotics2.6 Magnetically Guided2.7 Bacteria-Based 3 Nanorobots Market Overview by Application3.1 Global Nanorobots Market Size by Application: 2015 VS 2020 VS 20263.2 Global Nanorobots Historic Market Size by Application (2015-2020)3.3 Global Nanorobots Forecasted Market Size by Application (2021-2026)3.4 Nanomedicine3.5 Biomedical3.6 Others 4 Global Nanorobots Competition Analysis by Players4.1 Global Nanorobots Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nanorobots as of 2019)4.3 Date of Key Manufacturers Enter into Nanorobots Market4.4 Global Top Players Nanorobots Headquarters and Area Served4.5 Key Players Nanorobots Product Solution and Service4.6 Competitive Status4.6.1 Nanorobots Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Bruker5.1.1 Bruker Profile5.1.2 Bruker Main Business5.1.3 Bruker Nanorobots Products, Services and Solutions5.1.4 Bruker Nanorobots Revenue (US$ Million) & (2015-2020)5.1.5 Bruker Recent Developments5.2 Jeol5.2.1 Jeol Profile5.2.2 Jeol Main Business5.2.3 Jeol Nanorobots Products, Services and Solutions5.2.4 Jeol Nanorobots Revenue (US$ Million) & (2015-2020)5.2.5 Jeol Recent Developments5.3 Thermo Fisher5.5.1 Thermo Fisher Profile5.3.2 Thermo Fisher Main Business5.3.3 Thermo Fisher Nanorobots Products, Services and Solutions5.3.4 Thermo Fisher Nanorobots Revenue (US$ Million) & (2015-2020)5.3.5 Ginkgo Bioworks Recent Developments5.4 Ginkgo Bioworks5.4.1 Ginkgo Bioworks Profile5.4.2 Ginkgo Bioworks Main Business5.4.3 Ginkgo Bioworks Nanorobots Products, Services and Solutions5.4.4 Ginkgo Bioworks Nanorobots Revenue (US$ Million) & (2015-2020)5.4.5 Ginkgo Bioworks Recent Developments5.5 Oxford Instruments5.5.1 Oxford Instruments Profile5.5.2 Oxford Instruments Main Business5.5.3 Oxford Instruments Nanorobots Products, Services and Solutions5.5.4 Oxford Instruments Nanorobots Revenue (US$ Million) & (2015-2020)5.5.5 Oxford Instruments Recent Developments5.6 Ev Group5.6.1 Ev Group Profile5.6.2 Ev Group Main Business5.6.3 Ev Group Nanorobots Products, Services and Solutions5.6.4 Ev Group Nanorobots Revenue (US$ Million) & (2015-2020)5.6.5 Ev Group Recent Developments5.7 Imina Technologies5.7.1 Imina Technologies Profile5.7.2 Imina Technologies Main Business5.7.3 Imina Technologies Nanorobots Products, Services and Solutions5.7.4 Imina Technologies Nanorobots Revenue (US$ Million) & (2015-2020)5.7.5 Imina Technologies Recent Developments5.8 Toronto Nano Instrumentation5.8.1 Toronto Nano Instrumentation Profile5.8.2 Toronto Nano Instrumentation Main Business5.8.3 Toronto Nano Instrumentation Nanorobots Products, Services and Solutions5.8.4 Toronto Nano Instrumentation Nanorobots Revenue (US$ Million) & (2015-2020)5.8.5 Toronto Nano Instrumentation Recent Developments5.9 Klocke Nanotechnik5.9.1 Klocke Nanotechnik Profile5.9.2 Klocke Nanotechnik Main Business5.9.3 Klocke Nanotechnik Nanorobots Products, Services and Solutions5.9.4 Klocke Nanotechnik Nanorobots Revenue (US$ Million) & (2015-2020)5.9.5 Klocke Nanotechnik Recent Developments5.10 Kleindiek Nanotechnik5.10.1 Kleindiek Nanotechnik Profile5.10.2 Kleindiek Nanotechnik Main Business5.10.3 Kleindiek Nanotechnik Nanorobots Products, Services and Solutions5.10.4 Kleindiek Nanotechnik Nanorobots Revenue (US$ Million) & (2015-2020)5.10.5 Kleindiek Nanotechnik Recent Developments5.11 Xidex5.11.1 Xidex Profile5.11.2 Xidex Main Business5.11.3 Xidex Nanorobots Products, Services and Solutions5.11.4 Xidex Nanorobots Revenue (US$ Million) & (2015-2020)5.11.5 Xidex Recent Developments5.12 Synthace5.12.1 Synthace Profile5.12.2 Synthace Main Business5.12.3 Synthace Nanorobots Products, Services and Solutions5.12.4 Synthace Nanorobots Revenue (US$ Million) & (2015-2020)5.12.5 Synthace Recent Developments5.13 Park Systems5.13.1 Park Systems Profile5.13.2 Park Systems Main Business5.13.3 Park Systems Nanorobots Products, Services and Solutions5.13.4 Park Systems Nanorobots Revenue (US$ Million) & (2015-2020)5.13.5 Park Systems Recent Developments5.14 Smaract5.14.1 Smaract Profile5.14.2 Smaract Main Business5.14.3 Smaract Nanorobots Products, Services and Solutions5.14.4 Smaract Nanorobots Revenue (US$ Million) & (2015-2020)5.14.5 Smaract Recent Developments5.15 Nanonics Imaging5.15.1 Nanonics Imaging Profile5.15.2 Nanonics Imaging Main Business5.15.3 Nanonics Imaging Nanorobots Products, Services and Solutions5.15.4 Nanonics Imaging Nanorobots Revenue (US$ Million) & (2015-2020)5.15.5 Nanonics Imaging Recent Developments5.16 Novascan Technologies5.16.1 Novascan Technologies Profile5.16.2 Novascan Technologies Main Business5.16.3 Novascan Technologies Nanorobots Products, Services and Solutions5.16.4 Novascan Technologies Nanorobots Revenue (US$ Million) & (2015-2020)5.16.5 Novascan Technologies Recent Developments5.17 Angstrom Advanced5.17.1 Angstrom Advanced Profile5.17.2 Angstrom Advanced Main Business5.17.3 Angstrom Advanced Nanorobots Products, Services and Solutions5.17.4 Angstrom Advanced Nanorobots Revenue (US$ Million) & (2015-2020)5.17.5 Angstrom Advanced Recent Developments5.18 Hummingbird Scientific5.18.1 Hummingbird Scientific Profile5.18.2 Hummingbird Scientific Main Business5.18.3 Hummingbird Scientific Nanorobots Products, Services and Solutions5.18.4 Hummingbird Scientific Nanorobots Revenue (US$ Million) & (2015-2020)5.18.5 Hummingbird Scientific Recent Developments5.19 Nt-Mdt Spectrum Instruments5.19.1 Nt-Mdt Spectrum Instruments Profile5.19.2 Nt-Mdt Spectrum Instruments Main Business5.19.3 Nt-Mdt Spectrum Instruments Nanorobots Products, Services and Solutions5.19.4 Nt-Mdt Spectrum Instruments Nanorobots Revenue (US$ Million) & (2015-2020)5.19.5 Nt-Mdt Spectrum Instruments Recent Developments5.20 Witec5.20.1 Witec Profile5.20.2 Witec Main Business5.20.3 Witec Nanorobots Products, Services and Solutions5.20.4 Witec Nanorobots Revenue (US$ Million) & (2015-2020)5.20.5 Witec Recent Developments 6 North America6.1 North America Nanorobots Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Nanorobots Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Nanorobots Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Nanorobots Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Nanorobots Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Nanorobots Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Nanorobots Market Business Growth, Size and Comprehensive Research Study Forecast to 2026| Bruker, Jeol, Thermo Fisher - The Market Feed

Global Nanotechnology in Medical Market report explores the Nanotechnology in Medical industry around the globe offers details about industry review, classification, meaning, and possibility along with key regions and countries. This research report delivers detailed insights on each and every aspect of the Nanotechnology in Medical Market.

Additionally, the research study divided the market on the basis of product types, application as well as end-user industries of Shooting Ranges.A 360 degree summarize of the competitive scenario of the Global Nanotechnology in Medical Market is presented by Reportspedia, The recent study on the Nanotechnology in Medical market Analysis report provides information about this industry with a thorough assessment of this business.

Sample Copy of This [emailprotected]:

https://www.reportspedia.com/report/others/2015-2027-global-nanotechnology-in-medical-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64313#request_sample

Major Players in the Nanotechnology in Medical market are:

3MCytimmuneNovartisCamurusMerckAmgenAccessRocheCelgeneMitsui ChemicalsSmith and NephewPfizerDentsply International

Nanotechnology in Medical market growth has been segregated into the Americas, APAC, Europe, Middle East & Africa. The Nanotechnology in Medical market size is appropriately divided into pivotal segments in the report. A synopsis of the industry with regards to market size concerning remuneration and volume aspects along with the current Nanotechnology in Medical market shares scenario is also offered in the report.

Ask for [emailprotected]:

https://www.reportspedia.com/discount_inquiry/discount/64313

Types covered in the Nanotechnology in Medical industry are:

Nano MedicineNano DiagnosisOther

Applications covered in the report are:

HospitalsClinicsOthers

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for the Nanotechnology in Medical industry. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving the enlargement of the industry. Researchers have also focused on individual growth trends besides their contribution to the overall market.

This is probable to drive the Global Nanotechnology in Medical Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After study key companies, the report focuses on the new entrant contributing to the enlargement of the market. Most companies in the Global Nanotechnology in Medical Market are currently adopted new technological trends in the market.

Inquiry Before [emailprotected]:

https://www.reportspedia.com/report/others/2015-2027-global-nanotechnology-in-medical-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64313#inquiry_before_buying

Key highlights of the global Nanotechnology in Medical Market research report:

Some of the key questions answered in this Nanotechnology in Medical Market report:

Table of Contents: Nanotechnology in Medical Market

Chapter 1: Overview of Nanotechnology in Medical Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Nanotechnology in Medical Market Status and Forecast by Types

Chapter 4: Global Nanotechnology in Medical industry Status and Forecast by Downstream Industry

Chapter 5: Nanotechnology in Medical industry Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Nanotechnology in Medical industry Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Nanotechnology in Medical industry Market Report Conclusion

Chapter 12: Research Methodology and Reference

Get ToC for the overview of the premium report @:

https://www.reportspedia.com/report/others/2015-2027-global-nanotechnology-in-medical-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64313#table_of_contents

Here is the original post:
Nanotechnology in Medical Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

Oct. 1, 2020 11:30 UTC

Completes First Procedures in CellFX System Specific Indication Study

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System. The data generated from this study is intended to support a 510(k) submission to expand the indication for use of the CellFX System specifically to treat SH lesions.

Following IDE approval, several patients have been enrolled, with the first patient procedure completed on September 28, 2020. The multicenter prospective comparative study is intended to evaluate the safety and efficacy of procedures to clear facial SH lesions performed with the CellFX System versus those performed by electrodessication in a comparator group. Enrollment of 60 patients across five study sites is expected to be completed in approximately three months. All subjects will have up to two treatments and will be evaluated through the primary safety and efficacy endpoints at 60-days following their last treatment. The ClinicalTrials.gov Identifier for the study is NCT04539886.

We are pleased to have received FDA IDE approval and to have begun this important SH comparative study slightly ahead of the fourth quarter start we had previously communicated. Understanding the COVID-19 pandemic has increased the demand on FDA resources, we appreciate their attention throughout the IDE process. Barring delays in enrollment, we expect to conclude the study in the first quarter of 2021 and plan to quickly follow with a 510(k) submission for the corresponding specific indication. We have long viewed SH as a top addressable market priority for the CellFX System based on patient demand in clinics today and the CellFX Systems early demonstration of procedure effectiveness, said Darrin Uecker, President and CEO of Pulse Biosciences. As we have communicated previously, in parallel we are completing our GLP preclinical study in support of the initial CellFX System 510(k) submission for a general dermatologic indication. We remain on track to submit this 510(k) in the next several weeks.

About Sebaceous Hyperplasia

Sebaceous hyperplasia (SH) is a very common skin condition that presents as shiny, yellowish or white raised bumps, or lesions, that most frequently occur on the face and are often oily in appearance. SH lesions form on the skin surface when the sebaceous glands, which are located in the deeper layer of the skin, become enlarged and form bumps between 2 and 4 millimeters wide on the facial skin surface. These deeper sebaceous glands that cause the SH lesion are difficult to treat with current thermal technologies without damaging the skin surface.

Based on a 2019 survey1, dermatologists who specialize in aesthetic procedures see an average of over 40 patients per week with SH lesions and their surveyed aesthetic patients diagnosed with this common problem are highly motivated to seek treatment as a cash-paying procedure to improve the appearance of their facial skin. Yet the majority of these patients diagnosed with SH are untreated, likely due to limitations of existing treatments that either cannot reach the sebaceous gland or that damage the skin surface, making the skin appearance worse than prior to treatment. Given the profile of NPS technology as a new option to reach these sebaceous glands with more desirable cosmetic effects, in the same survey, 88% of these aesthetic dermatology specialists reported a clear interest in a new procedure to address SH lesions. Previously published clinical data by the Company demonstrated that over 90% of SH lesions were cleared or mostly cleared by 60 days post-NPS treatment.

1 2019 Physician (n=304) and Patient (n=405) surveys conducted by third-party market research firm on behalf of Pulse Biosciences, Inc.

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX System will be the first commercial product to harness the distinctive advantages of the Companys proprietary Nano-Pulse Stimulation (NPS) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit http://www.pulsebiosciences.com.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Caution: Pulse Biosciences CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences expectations regarding regulatory clearance and the timing of FDA and other regulatory filings or approvals, including meetings with FDA and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for a specific indication for the treatment of sebaceous hyperplasia (SH) lesions, the ability of the Company to prepare and provide data to FDA and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Companys market opportunity and commercialization plans, including the market for the treatment of SH, future financial performance, the impact of COVID-19 and other future events. These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors. Words such as may, will, could, would, should, anticipate, predict, potential, continue, expects, intends, plans, projects, believes, estimates, and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005320/en/

Read more here:
Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study - BioSpace

Written by AZoNanoOct 1 2020

When nanoparticles are injected into the bloodstream, for instance, to kill solid tumors, it is not known what exactly happens to them.

Now, with new results reported in the ACS Nano journal, scientists from Aarhus University are set to deal with this challenging query by using zebrafish embryos as a new research model in nanotoxicology and nanomedicine.

A wide range of nanoparticles are engineered for targeted drug delivery, but regrettably, just a few of the injected nanoparticles reach the site of target, such as solid tumors. The reason for this low targeting efficiency is frequently considered a black box and thus had not been investigated thoroughly for a number of years.

An international research group, headed by Yuya Hayashi from the Department of Molecular Biology and Genetics (MBG), Aarhus University, has now shown the beauty of zebrafish embryos in nano-bioimaging that can view dynamic interactions between nanoparticles and target cells in a living entity.

Currently, in association with scientists from Interdisciplinary Nanoscience Center (iNANO), Yuya aims to answer the unexplained mysteries in bionanosciencethe first one is the biological identity concept, which elucidates how cells detect nanoparticles via a corona of proteins surrounding each particle.

For the first time, this concept has now been demonstrated in a living organism through the use of zebrafish embryos, revealing what exactly occurs to nanoparticles when they are injected into the blood.

What the Cell Sees in Bionanoscience is one of the initial publications that have established how a protein corona develops around a nanoparticle and how this protein corona indicates the need for reconsidering the way one observes nanoparticles within a biological setting. From elaborate research made in the last several years, researchers have now understood that two opposing effects mostly play a role in the cellular uptake of nanoparticles.

Generally, the protein corona inhibits the surface of the nanoparticle from direct physical interactions with the cell membrane. But what if the protein corona sends a signal that activates a particular biological interaction with receptors positioned on the cell membrane? That is something the cell detects and therefore confers a biological identity to the nanoparticle.

Currently, the scientists from Aarhus University have thus given the first visual proof for the excellent influence of the protein corona with regard to the clearance of nanoparticles from the blood that involved adverse results in the zebrafish embryo model.

The researchers employed a species-mismatched source of proteins for the formation of corona to produce a non-self biological identity and traced the movement of nanoparticles traveling via the blood and to their final targetthat is, endolysosomes in the cell.

This showed an unexpectedly quick uptake and acidification of the nanoparticles by scavenger endothelial cells (functional counterpart to the liver sinusoidal endothelial cells in mammals) followed by pro-inflammatory stimulation of macrophages.

It sounds like a crazy idea to inject nanoparticles with proteins from another animal, but for example, biomolecule-inspired nanomedicines are tested in a mouse model without particular concerns for the species-mismatched combination.

Yuya Hayashi, Department of Molecular Biology and Genetics, Aarhus University

Hayashi continued, Or else some clever folks humanise the mouse to take care of the species compatibility problem. In fact, even at the cell culture level nanoparticles are still routinely tested following the tradition to use serum supplement derived from cows while knowing that nanoparticle-protein interactions are a key driver of cellular uptake.

What makes this kind of experiments rather challenging is to maximally retain the original protein corona in a living organism. If the pre-formed corona gets quickly exchanged by endogenous blood proteins, the hypothesis tested becomes invalid. We have made quite some efforts to characterise the protein corona to ensure the nanoparticles preserve the non-self-biological identity.

Hossein Mohammad-Beigi, Study First Author, Aarhus University

The maximum benefit of the zebrafish model is its power in multicolor immediate imaging, whereby numerous combinations of reporter proteins and fluorescence tracers can be viewed in a basic arrangement at high spatio-temporal resolution. This offers a new chance that lies between less lifelike cell culture systems and more complex rodent experiments, like intravital microscopy.

Using cell cultures, we have learnt quite a lot about how cells recognise nanoparticles rather as dynamic aggregates of proteins but it was never tested in a more realistic situation. With establishment of the zebrafish model, we have finally acquired a means to further explore this question in a living organism.

Yuya Hayashi, Department of Molecular Biology and Genetics, Aarhus University

It was a simple approach with an extreme scenario tested in a very complex system, but I believe we are now one step closer to understanding what the protein corona can really mean to nanoparticles. In an environment rich in proteins, nanoparticles can wear a mask that gives them a biological identity, and its non-selfness can make them a foe. What defines the degree of the non-selfness? Well, it's the next big question we have to address, Hayashi concluded.

Mohammad-Beigi, H., et al. (2020) Tracing the In Vivo Fate of Nanoparticles with a Non-Self Biological Identity. ACS Nano. doi.org/10.1021/acsnano.0c05178.

Source: https://mbg.au.dk/en

See original here:
Zebrafish Embryo Model Helps Understand the Workings of Nanoparticles in Blood - AZoNano

Manhattan, New York, Analytical Research Cognizance: TheNanomedicineMarketreport is based on the basis of product type, application and end-user during the truncated forecast period. The detailed study further offers a broad interpretation on the Nanomedicine market based on a systematic analysis of the market from a variety of reliable sources and thorough data points. Furthermore, the report sheds a light on the Global scale segmenting the market space across various districts, appropriate distribution channels, generated income and a generalized market space.

This intelligence and 2025 forecasts Nanomedicine industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and set a precedented growth trajectory for the Nanomedicine market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Request Sample of Global Nanomedicine Market Report @https://www.arcognizance.com/enquiry-sample/923566

Finally, the report provides detailed profile and data information analysis of leading Augmented Reality Company.

This report covers leading companies associated in Nanomedicine Market @GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A

Region Segmentation:North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)

On the basis of types, the Nanomedicine market is primarily split into:Regenerative Medicine, In-vitro & In-vivo Diagnostics, Vaccines, Drug Delivery

On the basis of applications, the market covers:Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology

Some of the major factors contributing to the growth of the global Nanomedicine market:

Nanomedicine Market Report Structure at a Glance:

Access Global Nanomedicine Market Report @https://www.arcognizance.com/report/global-nanomedicine-market-status-and-future-forecast-2015-2025

Table of Content:

Note:Our report does take into account the impact of corona virus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

About us:Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential. ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448[emailprotected]

Read the original here:
Impact Of Covid-19 on Nanomedicine Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Crypto Daily

For the optimal performance of CriPec nanomedicines, it is essential to be able to attach a broad range of small molecule active agents and large molecular entities, biologics, to CriPec nanoparticles.

The published research1reports the development of a convenient and versatile fast-reacting molecular entity for gluing very different compounds in a strain-promoted azide-alkyne cycloaddition click reaction to the nanoparticles, as well as a collection of linkers to attach the widely varying active small molecules and biologics. Next to the already demonstrated examples, many additional applications are foreseen such as the construction of antibody drug conjugates in aqueous environments with faster kinetics that is essential for these delicateconstructs.

CliCr is also used to generate virus mimicking nanoparticles. CriVac is a unique antigen carrier platform based on CriPec nanoparticles that, in contrast to viral vectors, do not convey a bystander immune response. CriPec particles' size resemble a virus and the desired numbers of antigen displayed on its surface are controlled via CliCr. CriVac mimics features of a live virus in a tailored manner to induce immunity safely, efficiently and solely to the displayed antigen, offering a prophylactic vaccination strategy which will be readily adaptable to different pathogenic treats.

The very attractive functionalisation possibilities, combined with its versatility, great reactivity and small size offer multiple opportunities for CliCrreagents to become the new standard for non-copper catalyzed click reactions in a multitude of applications.

Dr Cristianne Rijcken, CSO of Cristal Therapeutics, stated:

"This new versatile click reagent originates from an intense collaboration between industry and academic partners. For our nanomedicine applications, a fast, cleanly reacting and small click reagent is absolutely indispensable. These demands required the development of a new reagent, which will be highly attractive both for our proprietary applications and for the wider world of the biological, medical and material science applications. This is ground-breaking technology!"

In case you are interested to learn about the CliCr platform, please reach out to http://www.clicr.euor talk to us at the following virtual conferences

Reference

1. J. Weterings et al. TMTHSI, a superior 7-membered ring alkyne containing reagent for strain-promoted azidealkyne cycloaddition reactions, Chemical Science (2020)

https://pubs.rsc.org/en/content/articlehtml/2020/sc/d0sc03477k

About Cristal Therapeutics

Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company's product candidates are based on its proprietary CriPec polymeric nanoparticle technology platform, which enables the design of customized nanomedicines with superior therapeutic profiles. CriPec-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.

Find out more: http://www.cristaltherapeutics.com

For more information, please contact:

Cristal Therapeutics Jeroen van EgmondConsultant Business DevelopmentT: +31 6 272 048 89E: [emailprotected]

SOURCE Cristal Therapeutics

Read more:
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr technology platform, comprising a new class of superior copper free click...

Top for from left: Douglas Ellman, Branden Minei, Luke Campillo, Allexa Dow; Middle row from left: Marisa McDonald, Ashley McGuigan, John Runburg, Michael Honda, Priscilla Seabourn, Lauren Ching; Bottom row from left: Aileen Li, Brien Haun, Anamica Bedi de Silva, Trista McKenzie, Gagandeep Anand, Travis Berger

Sixteen University of Hawaii at Mnoa doctoral candidates have been awarded $5,000 Scholar Awards from the ARCS FoundationHonolulu Chapter. The 2020 awards were made in six UH Mnoa units.

ARCS Foundation works to advance science in America by providing unrestricted awards to outstanding U.S. graduate students in STEM fields. The chapter has provided more than $2 million to UH graduate students since 1974.

This award has not only provided monetary support for my research, but it shows that theres recognition for my work outside of my immediate sphere, and thats very meaningful, says ARCS Scholar Trista A. McKenzie.

McKenzie and her award donor are featured in the Honolulu Chapters first Meet-the-Scholar video, which was created after COVID-19 preempted the annual scholar presentations.

Douglas Ellman received the Bretzlaff Foundation Award in Engineering. He uses optimization and machine learning to study how distributed energy resources, such as solar batteries, electric vehicles and smart appliances, can be used to improve the operation of the electric grid.

Brenden M. Minei received the Frederick M. Kresser Award in Engineering. He developed a novel ceramic-based Nano-Paste that can be both 3D printed and molded to optimize and develop ceramic nanocomposite parts with armor as well as space structure and optical applications.

Read more about the College of Engineering scholars.

Luke Campillo received the Sarah Ann Martin Award in Natural Sciences. He sequences the DNA Hawaiian birds to study the impact of limited contact with other populations and competition for limited resources on speciation on island archipelagos.

Allexa Dow received the Ellen M. Koenig ARCS Award. She studies mechanisms employed by the deadly Mycobacterium tuberculosis pathogen to survive severe zinc depletion in the host, a necessary step for disease transmission.

Marisa S. McDonald received the Maybelle Roth ARCS Award in Conservation Biology. She is working to understand vision in larval mantis shrimp, focusing on ultraviolet vision function and use.

Ashley A. McGuigan received the ARCS Honolulu Award. She explores the connection between agroforest biodiversity and dietary nutrition in Fiji and the ways agroforestry helps people recover from major cyclone disturbances.

John Jack Runburg received the Sarah Ann Martin Award in Natural Sciences. He uses theoretical models and devises other methods to learn more about dark matter, the most common, but invisible, form of matter in the universe.

Read more about the College of Natural Sciences scholars.

Michael David Honda received the Kai Bowden ARCS Award. He is working to determine the mechanism of iron uptake in giant leucaena, which is used as a nutritious fodder-legume for farm animals.

Priscilla S. Seabourn received the Helen Jones Farrar Award. She uses DNA sequencing to characterize the microbiome and understand how environmental and ecological factors influence its diversity in Aedes albopictus mosquitoes, an insect that serves as a vector for Dengue and Chikungunya viruses, with an eye to improving strategies for disease prevention.

Read more about the CTAHR scholars.

Lauren Ching received the Koenig ARCS Award. She studies immunopathogenesis of Kawasaki disease, the leading cause of pediatric acquired heart disease in the developed world, to identify novel therapeutics that could ameliorate changes to coronary arteries.

Aileen S.W. Li received the Starbuck ARCS Award in Medicine. She uses in vitro model systems to understand the mechanisms of gastrulation, the foremost, crucial and sensitive stage of embryo development, and exposure to teratogens, agents that can cause birth defects.

Brien Haun received the Ellen M. Koenig ARCS Award. He is working to hack the immune system to uncover protective responses to emerging infectious viruses.

Read more about the JABSOM scholars.

Anamica Bedi de Silva received the George and Mona Elmore ARCS Award. She works on viral immunity in microbes, developing resistant strains of a single-cell algae for experimental evolution in the laboratory to determine if there are fitness costs to viral resistance.

Trista A. McKenzie received the Toby Lee ARCS Award in Earth Sciences. She studies groundwater pollution and discharge dynamics using a combination of field, lab and machine-learning approaches.

Read more about the SOEST scholars.

Gagandeep Deep Anand received the ARCS Honolulu Award. He is determining accurate distances to nearby galaxies using Hubble Space Telescope imaging to investigate the distribution of matter and evolution of galaxy groups and clusters.

Travis A. Berger received the Columbia Communications Award in Astronomy. He studies planet formation and evolution using stellar distances as measured by the Gaia space observatory of stars and exoplanets observed by the Kepler space telescope.

Read more about the IfA scholars.

Link:
UH Manoa scholars awarded ARCS Foundation grants for research - UH System Current News

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Exosome Diagnostic and Therapeutic Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Application ; Product ; End User, and Country" - https://www.reportlinker.com/p05974359/?utm_source=GNW

Exosome is an emerging industry with a huge potential.Applications of exosomes are expanding rapidly in the areas of disease diagnosis and treatment as well as pharmaceuticals.

Exosomes are nanovesicles and act as a vehicle to deliver therapies to cells of the body.In the future, exosomes can be used as potential biomarkers and in the field of personalized medicine.

Interest in exosome research has increased dramatically in recent years, driving the growth of the exosome diagnostic and therapeutic market in the UK.New exosome therapeutics companies are rapidly entering the marketplace.

The investment flow has also increased to support such innovative therapeutic companies, further boosting the growth of the market. For example, in 2016, ReNeuron Group plc, a leading UK-based stem cell therapy development company, was awarded about US$ 2.6 million grant from Innovate UK to advance its emerging exosome nanomedicine platform.In terms of application, the diagnostics application segment accounted for a larger share of the Europe exosome diagnostic and therapeutic market. Its growth is attributed to an increasing adoption of exosome-based instruments and kits for diagnosis of chronic conditions. Additionally, exosome-based diagnostic products offer benefits such as accuracy, lower processing time, and better ergonomics; these are likely to drive the growth of diagnostic application segment in the Europe exosome diagnostic and therapeutic marketIn 2019, the instrument segment held a considerable share of the for exosome diagnostic and therapeutic market, by the product.This segment is also predicted to dominate the market by 2027 owing to higher demand for diagnostics instruments.

However, the software segment is anticipated to witness growth at a significant rate during the forecast period.A few major primary and secondary sources for the exosome diagnostic and therapeutic market included in the report are Instrument, US Food and Drug Administration, and World Health Organization, among others.Read the full report: https://www.reportlinker.com/p05974359/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:
The Europe exosome diagnostic and therapeutic market is projected to reach US$ 12,524.24 thousand in 2019 to US$ 104,694.72 thousand by 2027 -...

Global Nanorobotics Market report study covers the breakdown data with production, consumption, revenue and market share by regions, type and applications. Historical breakdown data from 2015 to 2019 and forecast to 2024

The comprehensive numerical analyses of Global NanoroboticsMarket Research Report 20202024 is a historical overview and in-depth study on the current & future market of the Nanorobotics industry. he report focuses on the historical and current market trends to predict the course of the global Nanorobotics market in the upcoming years. The report identifies opportunities, drivers, and major challenges faced by market players. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments. The research further provides par excellence futuristic estimations for various vital factors including market size, share, net profit, sales, revenue, and growth rate. The market competition by top manufacturers/players, with sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including market:Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik. This report provides in-depth analysis of the Nanorobotics market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (20202024).

Request for Sample Report @https://www.indexmarketsresearch.com/report/global-nanorobotics-market/431987/#requestforsample

Global major manufacturers of the market are also assessed with their information such as company profiles, product picture and specification, capacity, production, price, cost, market trend, revenue, and contact data. The research provides details regarding each product like the cost breakup, import/export scheme, manufacturing volume, price, gross, growth ratio, investments, and contribution to the global Nanorobotics revenue. The facts and data are represented in the Nanorobotics Market report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better. We have provided a detailed study on the critical dynamics of the global Nanorobotics market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. Global Nanorobotics Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details. The research study also includes other types of analysis such as qualitative and quantitative. The document also comprises of a detailed assessment of the regional scope of the market alongside its regulatory outlook. Additionally, the report provides with a detailed SWOT analysis while elaborating market driving factors. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. Nanorobotics market report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

The Nanorobotics market report includes the overall and comprehensive study of the Nanorobotics market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Nanorobotics industry and provides data for making strategies to increase the market growth and effectiveness. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report will help you to establish a landscape of industrial development and characteristics of the Nanorobotics market. The Global Nanorobotics market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. It also provides statistical data on all the recent developments in the market. It also comprises a basic overview and revenue and strategic analysis under the company profile section. Nanorobotics market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

Regional Analysis:This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report areNorth America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and SouthAfrica)Information about the different regions helps the reader to better understand the global Nanorobotics market.

Most important types of the market covered in this report are:Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based

Most widely used downstream fields of market covered in this report are:Nanomedicine, Biomedical, Mechanical

Research objectives: The points that are discussed within the Nanorobotics Market report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. To analyze the Nanorobotics with respect to individual growth trends, future prospects, and their contribution to the total market. Focuses on the key global Nanorobotics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To project the consumption of Nanorobotics submarkets, with respect to key regions (along with their respective key countries). To strategically profile the key players and comprehensively analyze their growth strategies. The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. The Nanorobotics market report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions Answered: What is the size and CAGR of the global World Nanorobotics Market? Which are the leading segments of the global World Nanorobotics Market? What are the key driving factors of the most profitable regional market? What is the nature of competition in the global World Nanorobotics Market? How will the global Home Appliance market advance in the coming years? What are the main strategies adopted in the global World Nanorobotics Market? What are sales, revenue, and price analysis by types and applications of Nanorobotics market? What are sales, revenue, and price analysis by regions of Nanorobotics industry?

The Essential Content Covered in the Global Nanorobotics Market Report :* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Read Detailed Index Report @https://www.indexmarketsresearch.com/report/global-nanorobotics-market/431987/

The Nanorobotics market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies. This report is comprehensive numerical analyses of the Nanorobotics industry and provides data for making strategies to increase the market growth and success. The Report also estimates the market size, Price, Revenue, Gross Margin and Market Share, cost structure and growth rate for decision making. A detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, threats, and global markets including progress trends, competitive landscape analysis, and key regions expansion status.

At last, This report investigates the Nanorobotics market in the global market, presents the latest business analysis including market scope, product situation, technology growth, environmental distribution, business situation, and chain structure. industrial. Nanorobotics Market Report Shares Important Data on Impact Factors, Advertising Drivers, Challenges, the report gives the inside and out examination of Nanorobotics Market took after by above components, which are useful for organizations or individual for development of their present business or the individuals who are hoping to enter in Nanorobotics industry.

Request customize If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @[emailprotected]

View post:
Nanorobotics Market to Witness Huge Growth by 2024 | Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments - The Daily Chronicle

Nanoscience has made an impact on a range of industries. With continuous developments, it will only get more exciting for investors.

Through nanotechnology, nanoscience has undeniably impacteda range of industries, from energy to medicine. In the face of continuous nanotechnology research and development, experts are promising an exciting future for the industry.

The terms nanoscience and nanotechnology have been around for a long time, and its common for them to be used interchangeably. However, its important to note that they are not the same.

According toErasmus Mundus, the European Unions higher education program, nanoscience refers to the study, manipulation and engineering of particles and structures on a nanometer scale. For its part, nanotechnology is described as the design and application of nanoscience.

In simple terms, nanoscience is the study of nanomaterials and properties, while nanotechnology is using these materials and properties to create a new product.

Here the Investing News Network provides a comprehensive look at nanoscience investing and nanomaterials, with an overview of the subjects and where they are headed in the future.

The University of Sydneys Nano Institute describes nanoscience as the study of the structure and function of materials on the nanometer scale.

Nanometers are classified as particles that are roughly the size of about 10 atoms in a row. Under those conditions, light and matter behave in a different way as compared to normal sizes.

These behaviours often defy the classical laws of physics and chemistry and can only be understood using the laws of quantum mechanics, the universitys research page states.

The Institute of Nanoscience of Aragon identifies carbon nanotubes (CNTs) as one example of a component that is designed at the nanoscale level. These structures are stronger than steel at the macroscale level. CNT powders are currently used in diverse commercial products, from rechargeable batteries to automotive parts to water filters.

Scientists, researchers and industry experts are enthusiastic about nanoscience and nanoparticles.

As noted in a study published by Jeffrey C. Grossman, a University of California student, quantum properties come into play at the nanoscale level. In simple terms, at the nanoscale level, a materials optical properties, such as color, can be controlled.

Further, the paper states that the surface-to-volume ratio increases at the nano size, opening up new possibilities for applications in catalysis, filtering, and new composite materials, to name only a few.

In other words, the opening up of surface area, which adds new possibilities, can have drastic effects on industries such as manufacturing. New applications in catalysis can allow manufacturing to be sped up, while new composite materials can add more dimension to an end product.

Nanoscale developments could also lead to increased resources and could play a role in the energy sector by increasing efficiency.

As the Royal Society putsit, the aim of nanoscience and nanotechnologies is to produce new or enhanced nanoscale materials.

Nanomaterials are formed when materials have their properties changed at the nanoscale level. Nanomaterials involve elements that contain at least one nanoscale structure, but there are several subcategories of nanomaterials based on their shape and size.

According to the Royal Society, nanowires, nanotubes and nanoparticles like quantum dots, along with nanocrystalline materials, are said to be nanomaterials.

While these are broader classifications of nanomaterials, each of them has several submaterials. Graphene is one popular submaterial and is an example of a nanoplate.

The Integrated Nano-Science & Commodity Exchange, a self-regulated commodity exchange, includes a wide range of nanomaterials and related commodities and lists more than 1,000 nanomaterials.

The exchange states that its entire product range is in excess of 4,500 products, including CNTs, graphene, graphite, ceramics, drug-delivery nanoparticles, metals, nanowires, micron powders, conductive inks, nano-fertilizers and nano-polymers.

As can be seen, nanoscience and nanotechnology are used in a variety of applications across diverse fields, from energy to manufacturing. The University of Sydneys Nano Institute highlights how nanoscienceimpacts manufacturing, energy and the environment through the continuous development of new nano and quantum materials.

With the advancement of materials science and technology, solutions are being worked on for the health and medicine fields, with nanobots gaining popularity in the medical field.

Similarly, nanomaterials like graphene are having a major impact in the technology field graphene is used for various purposes, including in cooling and in batteries.

According to IndustryARC, the global nanotechnology market is projected to reach US$121.8 billion by 2025, growing at a compound annual growth rate of 14.3 percent between 2020 and 2025.

In the US, the National Nanotechnology Initiative, a US government research and development initiative that involves 20 federal and independent agencies, has received cumulative funding of US$27 billion since 2001 to advance research and development of nanoscale projects.

With growth predicted across multiple areas and industries, and with researchers and institutes working on developing the nanoscience field, investors have a slew of nanotechnology stocks to consider.

One popular investment avenue is via graphene, with companies in the space including Applied Graphene Materials (LSE:AGM,OTC Pink:APGMF) and Haydale Graphene Industries (LSE:HAYD). Meanwhile, nanotech stock options include firms such as NanoViricides (NYSE:NNVC), Nano Dimension (NASDAQ:NNDM) and Sona Nanotech (CSE:SONA).

This is an updated version of an article first published by the Investing News Network in 2019.

Dont forget to follow us @INN_Technology or real time updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

Read more:
What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network

Bioengineering professor Andrew Tsourkas leads the TITAN Lab. (Photo from Andrew Tsourkas)

The National Institutes of Health awarded a Penn Engineering lab and Penn-based startup $667,000 to improve COVID-19 detection technology.

Led by Bioengineering professor Andrew Tsourkas, the Targeted Imaging Therapeutics and Nanomedicine (Titan) Lab partnered with AlphaThera, a startup located at the Pennovation Center, to improve the ELISA technology, which is widely used to detect COVID-19 infections. ELISA, also known as enzyme-linked immunosorbent assay, is used to detect antibodies, proteins the body makes to fight an infection like COVID-19.

By improving ELISA technology, the Titan lab and AlphaThera will enable faster and more sensitive antibody tests for COVID-19 patients. According to the Centers for Disease Control and Prevention, antibody tests may allow patients to determine if they have previously been infected with COVID-19, but do not detect a current COVID-19 infection.

James Hui, who founded AlphaThera alongside Tsourkas, said the company has been working on reducing the time it takes to complete an ELISA assay in detecting antibodies for COVID-19.

These assays can take anywhere between three hours to six hours, but we can do these ELISA assays about probably half the time if not more," said Hui, who received a Ph.D. in Bioengineering from Penn in 2015 and Doctor of Medicine from the Perelman School of Medicine in 2017.

AlphaThera is responsible for developing the ELISA assays, while Tsourkas lab conducts pre-clinical testing for further development of the technology before testing on human samples. After AlphaThera's assays have been validated with the test samples, the team will begin clinical trials in Ping Wang lab at Penn Medicine on about 80 human samples from both COVID-19 and non-COVID-19 patients, Tsourkas said.

The main benefit for the lab is that it shows a practical application for some basic technology we developed in the lab, Tsourkas said. It's always nice to see something turned into a product and be useful for laboratories beyond our own.

Tsourkas said his lab's research also focuses on improving ELISA's sensitivity to detect antibodies, which will help healthcare workers identify a greater number of patients who were previously infected with the virus.

We have some cool antibody labeling technologies that we think will give us a significant boost in sensitivity and how rapid we can read out whether the patient has those antibodies in their serum, he said.

Their goal is to have the technology's validation studies be completed and for kits to be made available to the public within a year, Tsourkas said.

Vaccines imitate an infection while almost never causing illness, prompting the body to produce antibodies and white blood cells that will remember how to fight the disease in the future. Tsourkas said, therefore, fast antibody tests to determine whether a vaccine has prompted the body to produce antibodies will become more important as vaccine development progresses.

As vaccines are being developed now, we need to check to see whether they're working and to see how much of the population was really exposed [to the virus]," Tsourkas said.

Get our newsletter, Dear Penn, delivered to your inbox every weekday morning.

Tsourkas' research can also be applied to other antibody-detecting assays already on the market to improve their speed and sensitivity, he said.

While AlphaThera has been working to make the technology commercially viable and competitive in the market, Hui said their priority is to ensure the assays' speed and sensitivity in detecting antibodies.

We're not trying to be the first to roll off the market and try to get as much sales as possible, he said. Ultimately, we are a technology company [that is] more interested in developing a better product.

More:
Penn lab and startup awarded $667000 NIH grant to improve COVID-19 antibody testing - The Daily Pennsylvanian

PLAM BEACH, Fla., Sept. 16, 2020 /PRNewswire/ --The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach nanomedicine. The NIH said that nanomedicine is a promising approach fordiagnosis, treatment and prophylaxis against COVID-19. They said that: "The COVID-19pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind huge human losses and deep socioeconomic damages. Due to the lack of specific treatment against SARS-CoV-2, effective vaccines and antiviral agents are urgently needed to properly restrain the COVID-19 pandemic. Repositioned drugs such asremdesivir have revealed a promising clinical efficacy against COVID-19. Interestingly, nanomedicine as a promising therapeutic approach could effectively help win the battle between coronaviruses and host cells."Mentioned in today's commentary include: NanoViricides, Inc. (NYSE: NNVC), Immunomedics(NASDAQ: IMMU), Gilead Sciences, Inc. (NASDAQ: GILD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Novavax, Inc. (NASDAQ: NVAX).

Due to a lack of approved vaccines and specific treatments only preventive measures can currently be applied. Currently, development of an effective vaccine and specific treatment is the main concern for researchers worldwide to fight the current COVID-19 and any future mutations. Understanding the coronaviral genome and the processes of viral replication and pathogenesis will enable researchers to develop specific drugs and vaccines. So researchers are turning to nanomedicine, one of the most important and emerging fields of modern science.

NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.

The Company has accelerated its drug development program for COVID-19 with the goal of creating the most effective medicine to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible, after achieving proof of concept of broad-spectrum anti-coronavirus effectiveness of test candidates. The Company therefore aggressively worked to harness the full power of the nanoviricides nanomedicine platform to achieve these objectives.

A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) ability of the virus to infect host cells and simultaneously, (ii) ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies.

The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infected cells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally, remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled by NV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level can be attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness of NV-CoV-1-R.

Remdesivir is a well-known antiviral drug (developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries. NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness. It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside form which is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapid metabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may lead to increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction in the required dosage of remdesivir in the encapsulated form, i.e. as NV-CoV-1-R. In this sense, NV-CoV-1 can be viewed to act as an adjuvant that enhances the effect of remdesivir, a known antiviral against SARS-CoV-2.

"This is an extremely important milestone for the Company," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic." Read the full press release by going to: http://www.nanoviricides.com/companynews.html

In other biotech news in the markets this week:

Immunomedics(NASDAQ: IMMU) and Gilead Sciences, Inc. (NASDAQ: GILD)recently announcedthat the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.

The agreement will provide Gilead with TrodelvyTM(sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide."

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, recently announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisherjoins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800. With its consortium of third-party manufacturers, INOVIO plans to have 1001million doses of INO-4800 manufactured in 2021, subject to FDA approval of INO-4800 for use as a COVID-19 vaccine.Thermo Fisherplans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the US. At peak capacity,Thermo Fisherprojects that it could produce at least 100 million doses of INO-4800 annually.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, recently announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax' COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to overtwo billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary MatrixM adjuvant.

"Today's agreement with Serum Institute enhances Novavax' commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email: [emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Read more:
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID - PRNewswire

Healthcare Nanotechnology Market2020-2025 report offerscomprehensive quantitative and qualitative market analysis. This report has been prepared under the continuous observation of the global market situation. This report has been formulated to give our clients the most up to date data and analyses of the Healthcare Nanotechnology Market. The impact on the enterprises and business development, distribution by region and global level is assessed in the report.

Top Companies are covering This Report:-

AmgenStrykerTeva PharmaceuticalsUCBRocheAbbottMerck & CoCelgeneBiogenSanofiLeadiant BiosciencesShireKyowa Hakko KirinGilead SciencesJohnson & Johnson3M CompanyEndo InternationalSmith & NephewPfizerIpsen

The research process involved the study of various factors affecting the industry such as government policy, market environment, competitive landscape, historical data, existing trends in the market, and market risks, opportunities, market barriers and challenges.

Reports Intellect projects Healthcare Nanotechnology Market based on elite players, present, past, and forecast data for the coming years which will act as a profitable guide for all the market competitors. The study includes growth trends, micro- economic and macro-economic indicators in detail and the report has been assessed with the help of PESTEL analysis and other essential analyses operating in the Healthcare Nanotechnology Market. Top-down and bottom-up approaches are used to validate the global Healthcare Nanotechnology market size and estimate the market size for Company, regions segments, product segments and Application.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/905451

The report offers all the essential data for players to secure a position of strength in the market, all while creating a comprehensive action plan. Our analysts here at Reports Intellect have used advanced primary and secondary research techniques to create the most up to date assessment of data on the Healthcare Nanotechnology Market which opens up a plethora of new opportunities to create new strategies to gain leverage over the competition.

Type Coverage:

NanomedicineNano Medical DevicesNano DiagnosisOthersNanomedicine has the highest percentage of revenue by type, with more than 86% in 2019.

Application Coverage:

AnticancerCNS ProductAnti-infectiveOthersAccording to the application, anticancer and CNS products accounted for 17.56% and 22.70% of the market in 2019 respectively.

Market Segment by Regions, regional analysis covers

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/905451

Why us:

Reasons to buy:

About Us:-

Contact Us:

Sales@reportsintellect.com

PH + 1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Read more here:
Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva...

The eyes of many insects, including the fruit fly, are covered by a thin and transparent coating made up of tiny protuberances with anti-reflective, anti-adhesive properties. An article published in the journalNaturereveals the secrets of how this nano-coating is made. The authors, from the University of Geneva (UNIGE) and University of Lausanne (UNIL) - together with ETH Zurich (ETHZ) - show that the coating only consists of two ingredients: a protein called retinin and corneal wax. These two components automatically generate the regular network of protuberances by playing the roles of activator and inhibitor, respectively, in a morphogenesis process modelled in the 1950s by Alan Turing. The multi-disciplinary team even succeeded in artificially reproducing the phenomenon by mixing retinin and wax on different kinds of surface. This process, which is very inexpensive and is based on biodegradable materials, was used to obtain nano-coatings with a morphology similar to that of insects, with anti-adhesive and anti-reflective functionalities that could have numerous applications in areas as diverse as contact lenses, medical implants and textiles.

"The nano-coating that covers the surface of the eyes of some insects was discovered in the late 1960s in moths," begins Vladimir Katanaev, a professor in the Department of Cell Physiology and Metabolism in UNIGE's Faculty of Medicine and the study's lead investigator. "It's made up of a dense network of small protrusions about 200 nanometres in diameter and several dozens of nanometres in height. It has the effect of reducing light reflection."

The cornea of an insect without a coating typically reflects about 4% of the incident light, whereas the proportion drops to zero in insects that do have the covering. Although an improvement of 4% may seem small, it is enough of an advantage - especially in dark conditions - to have been selected during evolution. Thanks to its anti-adhesive properties, the coating also provides physical protection against the tiniest dust particles in the air.

Professor Katanaev moved into this research field ten years ago. In 2011, he and his team were the first to discover the nano-coating on the eyes of fruit flies (Drosophila melanogaster). This insect is much more suited to scientific research than moths, in particular because its genome has been completely sequenced.

The Geneva-based researcher has now gathered more evidence to support this hypothesis. Thanks to biochemical analyses and the use of genetic engineering, Professor Katanaev and his colleagues have succeeded in identifying the two components involved in the reaction-diffusion model developed by Turing. This hinges on a protein called retinin and wax produced by several specialised enzymes, two of which have been identified. Retinin plays the role of activator: with its initially unstructured shape, it adopts a globular structure upon contact with the wax and begins to generate the pattern. The wax, on the other hand, plays the role of inhibitor. The powerplay between the two leads to the emergence of the nano-coating.

Initial tests have shown that the coating is resistant to 20 hours of washing in water (it is easily damaged by detergent or scratching, although technological improvements could make it more robust). The anti-reflective properties have already aroused a certain degree of interest among manufacturers of contact lenses, while the anti-adhesive properties could appeal to the producers of medical implants. Indeed, this type of coating could make it possible to control where human cells hook on. Industry already has the techniques needed to obtain this outcome. But they use harsh methods, such as lasers or acids. The Geneva team's solution has the advantage of being inexpensive, benign and totally biodegradable.Reference:

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Nanoscale Reflective Coating Reverse-Engineered From Fly Eyes - Technology Networks

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Healthcare Nanotechnology (Nanomedicine) market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Healthcare Nanotechnology (Nanomedicine) market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Healthcare Nanotechnology (Nanomedicine) market to assist our clients arrive at beneficial business decisions.

The Healthcare Nanotechnology (Nanomedicine) market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Healthcare Nanotechnology (Nanomedicine) market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

What pointers are covered in the Healthcare Nanotechnology (Nanomedicine) market research study?

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Healthcare Nanotechnology (Nanomedicine) market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Healthcare Nanotechnology (Nanomedicine) market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Healthcare Nanotechnology (Nanomedicine) market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Healthcare Nanotechnology (Nanomedicine) market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Some of the Major Highlights of TOC covers:

See original here:
R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 - The Daily Chronicle

A detailed overview of Medical Biomimetics market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Medical Biomimetics market in conjunction with the geographical landscape, demand spectrum, remuneration scale, and growth graph of this vertical have also been included in this report.

Increasing rate of organ failure coupled with growing geriatric population base will act as growth impact rendering factors for medical biomimetics market during the forecast timeframe. As per the U.S. Census Bureau?s 2017 National Population Projections, there will be nearly 78 million people aged more than 65 years, while 76.7 million under 18 years of age in the U.S. by 2035, thereby escalating demand for biomimetics products in coming future.

High adoption of western culture, unhealthy diet and physical inactivity has led to rising incidence of cardiovascular diseases, resulting in increased demand for biomimetic cardiovascular products. Numerous applications of biomimetics in healthcare industry including fields such as dentistry, orthopedics, cardiovascular, and ophthalmology should stimulate business growth during the analysis period.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5768

Medical Biomimetics Market will reach over USD 35 billion by 2025; as per a new research report.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5768

Orthopedic product segment accounted for more than 30% market share in 2018 and is estimated to witness significant growth during the forecast period owing to growing demand for orthopedic prosthesis and implants. For instance, increasing number of accidents and injuries have escalated the demand for prosthetic limbs. Technological advancements including development of augment bone graft should positively impact segmental growth.

Application segment of medical biomimetics market includes plastic surgery, wound healing, tissue engineering, drug delivery and others including nanomedicine, drug discovery, enzymatic modification and medical engineering. Plastic surgery application segment will witness 6.3% CAGR over the coming years due to wide application of biomimetics in plastic surgery for scaffold formation. It is also used in craniofacial surgery for restoration of facial aesthetics, function and form.

Increasing R&D activities pertaining to development of innovative biomimetic products along with advancements in nanotechnology, tissue engineering utilizing biomimetics technology should positively impact industry expansion. However, high capital investment in R&D along with stringent regulations will hinder industry growth during the forecast timeframe.

Germany medical biomimetics market dominated European region in 2018 and is anticipated to grow at 5.8% during the forecast period. High technological adoption, rising geriatric population prone to suffer from organ failure and increasing incidence of ophthalmology, orthopedic and cardiovascular disorders in the country are driving factors for Germany medical biomimetics market.

Saudi Arabia medical biomimetics market will witness 5.2% CAGR during the forecast timeframe. Growing demand and adoption of cosmetic surgical procedures among women, technological advancements and rising awareness should drive Saudi Arabia medical biomimetics industry during the analysis period. Rising incidence of coronary heart disease coupled with growing uptake of unhealthy habits such as alcohol consumption and tobacco smoking will augment demand for biomimetic products in the region.

Major Highlights from Table of contents are listed below for quick lookup into Medical Biomimetics Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Medical Biomimetics industryInsights

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/5768

Go here to read the rest:
Medical Biomimetics Market research, Industry Outlook, Current Trends and Forecast by 2025 - The Research Process

Nanomedicine Market Overview:

Reports and Data has recently published a new research study titled Global Nanomedicine Market that offers accurate insights for the Nanomedicine market formulated with extensive research. The report explores the shifting focus observed in the market to offer the readers data and enable them to capitalize on market development. The report explores the essential industry data and generates a comprehensive document covering key geographies, technology developments, product types, applications, business verticals, sales network and distribution channels, and other key segments.

The report is further furnished with the latest market changes and trends owing to the global COVID-19 crisis. The report explores the impact of the crisis on the market and offers a comprehensive overview of the segments and sub-segments affected by the crisis. The study covers the present and future impact of the pandemic on the overall growth of the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1048

Competitive Landscape:

The global Nanomedicine market is consolidated owing to the existence of domestic and international manufacturers and vendors in the market. The prominent players of the key geographies are undertaking several business initiatives to gain a robust footing in the industry. These strategies include mergers and acquisitions, product launches, joint ventures, collaborations, partnerships, agreements, and government deals. These strategies assist them in carrying out product developments and technological advancements.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson.

An extensive analysis of the market dynamics, including a study of drivers, constraints, opportunities, risks, limitations, and threats have been studied in the report. The report offers region-centric data and analysis of the micro and macro-economic factors affecting the growth of the overall Nanomedicine market. The report offers a comprehensive assessment of the growth prospects, market trends, revenue generation, product launches, and other strategic business initiatives to assist the readers in formulating smart investment and business strategies.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/nanomedicine-market

Product Outlook (Revenue, USD Billion; 2017-2027)

Drug Delivery System Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

Key Coverage in the Nanomedicine Market Report:

Thank you for reading our report. Please get in touch with us if you have any queries regarding the report or its customization. Our team will make sure the report is tailored to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Hydroxycitronellal Market: Hydroxycitronellal Market To Reach USD 192.7 Million By 2027

Sterile Filtration Market: Sterile Filtration Market To Reach USD 8.48 Billion By 2027 | CAGR: 7.7%

Tissue Diagnostics Market: Tissue Diagnostics Market To Reach USD 5.02 Billion By 2027

UV-C Robot Market: UV-C Robot Market to Reach USD 1.46 Billion by 2027

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

Read this article:
Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment...

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary proxy statement/consent solicitation statement/prospectus, in connection with its recently-announced proposed business combination with Clene Nanomedicine, Inc. ("Clene"), a clinical-stage biopharmaceutical company developing a potential therapeutic nanocatalyst for the treatment of neurodegenerative diseases in addition to a nanotechnology based-therapy with antiviral applications.

Tottenham's ordinary shares are currently traded on Nasdaq under the symbol "TOTA". In connection with the closing of the transaction, Tottenham intends to change its name to Clene Inc., reincorporate in Delaware (by merging with Chelsea Worldwide Inc.) and remain Nasdaq-listed under a new ticker symbol. Completion of the transaction is subject to approval by Tottenham shareholders, Clene's stockholders, the Registration Statement being declared effective by the SEC, a concurrent closing of private placements and other customary closing conditions.

Chardan is acting as the M&A advisor to Tottenham. LifeSci Capital LLC is acting as the M&A advisor to Clene. Loeb & Loeb LLP is acting as legal advisor to Tottenham. Kirkland & Ellis LLP along with Stoel Rives LLP, Clene's local counsel, are acting as legal advisors to Clene.

About Clene Nanomedicine, Inc.

Clene Nanomedicine, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the development of unique therapeutic candidates for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based inSalt Lake City, Utahwith R&D and manufacturing operations located inNorth East, Maryland. For more information, please visitwww.clene.com.

About Tottenham Acquisition I Limited

Tottenham Acquisition I Limited is a blank check company formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities. Tottenham's efforts to identify a prospective target business were not limited to a particular industry or geographic region, although the company initially focused on operating businesses in the TMT (Technology, Media, Telecom), education, e-commerce, health-care and consumer goods industries with primary operations inAsia(with an emphasis inChina).

Forward-Looking Statements

This press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties identified in the Form S-4 filed by Chelsea Worldwide relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission ("SEC") made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Important Information

Chelsea Worldwide Inc., Tottenham, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Tottenham ordinary shares in respect of the proposed transaction described herein. Information about Tottenham's directors and executive officers and their ownership of Tottenham's ordinary shares is set forth in Tottenham's Annual Report on Form 10-K filed with the SEC, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation are included in the Form S-4 pertaining to the proposed transaction. These documents can be obtained free of charge from the sources indicated below.

In connection with the transaction described herein, Chelsea Worldwide Inc. will file relevant materials with the SEC including a Registration Statement on Form S-4. Promptly after the Registration Statement is declared effective, Tottenham will mail the proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF TOTTENHAM ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT TOTTENHAM WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TOTTENHAM, CLENE AND THE TRANSACTION. The proxy statement/consent solicitation/prospectus and other relevant materials in connection with the transaction (when they become available), and any other documents filed by Tottenham with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov).

SOURCE Tottenham Acquisition I Limited

See the article here:
Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with...